» Authors » Steven Deitelzweig

Steven Deitelzweig

Explore the profile of Steven Deitelzweig including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 52
Citations 474
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Deitelzweig S, Bergrath E, Di Fusco M, Kang A, Savone M, Cappelleri J, et al.
Future Cardiol . 2022 Apr; 18(5):393-405. PMID: 35360925
To compare real-world effectiveness/safety of non-vitamin K antagonist oral anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation. A systematic review of electronic databases yielded 7661 citations published...
12.
Deitelzweig S, Keshishian A, Zhang Y, Kang A, Dhamane A, Luo X, et al.
JACC CardioOncol . 2021 Oct; 3(3):411-424. PMID: 34604802
Background: Patients with cancer are more likely to develop nonvalvular atrial fibrillation (NVAF). Currently there are no definitive clinical trials or treatment guidelines for NVAF patients with concurrent cancer. Objectives:...
13.
Peacock W, Levy P, Diercks D, Li S, Wang T, McCord J, et al.
Crit Pathw Cardiol . 2021 Sep; 20(4):173-178. PMID: 34494982
Background: Whether American College of Cardiology (ACC) Chest Pain Center (CPC) accreditation alters guidelines adherence rates is unclear. Methods: We analyzed patient-level, hospital-reported, quality metrics for myocardial infarction (MI) patients...
14.
Lip G, Keshishian A, Zhang Y, Kang A, Dhamane A, Luo X, et al.
JAMA Netw Open . 2021 Aug; 4(8):e2120064. PMID: 34398204
Importance: Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic kidney disease...
15.
Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Klem C, et al.
Adv Ther . 2021 May; 38(6):3166-3184. PMID: 33963511
Introduction: Non-valvular atrial fibrillation (NVAF) is often accompanied by multiple comorbid conditions, which increase the associated risks and complexity of patient management. This study evaluated the risk of stroke/systemic embolism...
16.
Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Balachander N, et al.
Therap Adv Gastroenterol . 2021 Apr; 14:1756284821997352. PMID: 33815568
Background: Gastrointestinal (GI) bleeding is the most common type of major bleeding associated with oral anticoagulant (OAC) treatment. Patients with major bleeding are at an increased risk of a stroke...
17.
Deitelzweig S, Di Fusco M, Kang A, Savone M, Mokgokong R, Keshishian A, et al.
Curr Med Res Opin . 2021 Mar; 37(6):891-902. PMID: 33686900
Objective: To conduct a systematic review and network meta-analysis of real-world evidence comparing adherence, persistence, cost, and utilization between oral anticoagulant (OAC) in non-valvular atrial fibrillation (NVAF) patients. Methods: A...
18.
Hill J, Garcia D, Crowther M, Savage B, Peress S, Chang K, et al.
Blood Adv . 2020 Nov; 4(21):5373-5377. PMID: 33137202
Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appear to be at increased risk for venous thromboembolism (VTE), especially if they become critically ill with COVID-19. Some centers...
19.
Deitelzweig S, Dhamane A, Di Fusco M, Russ C, Rosenblatt L, Lingohr-Smith M, et al.
J Med Econ . 2020 Oct; 23(12):1389-1400. PMID: 33021129
Objective: To evaluate utilization of anticoagulants (ACs) and the predictors of treatment of patients with a diagnosis of atrial fibrillation (AF) during a hospital stay in the USA. Methods: Patients...
20.
Lip G, Keshishian A, Kang A, Dhamane A, Luo X, Klem C, et al.
Eur Heart J Cardiovasc Pharmacother . 2020 Oct; 7(5):405-414. PMID: 33010157
Aims: Polypharmacy is prevalent among non-valvular atrial fibrillation (NVAF) patients and presents a potential issue for the effective management of NVAF. This study compared the risk of stroke/systemic embolism (SE)...